Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

R&D (research and development) tops Irish diagnostics agenda:

This article was originally published in Clinica

Executive Summary

Diagnostics R&D ranked high on the agenda of the Irish Medical Devices Association's first diagnostics forum, held in Dublin on January 23 (see Clinica No 993, p 9). "Cost remains a primary issue, particularly because the Irish industry is so export-based," IMDA director Sharon Higgins told Clinica. "We are more and more trying to enable companies to move up the product value chain, with a view to improving competitiveness," she added. The forum also discussed developments in training. IMDA's competency-based assessment programme, currently in its final pilot phase, has been "very well received by the industry at large, and is being taken up by diagnostics companies as well," said Ms Higgins. IMDA has decided to make the meeting a regular biannual event.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT064536

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel